,

Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease

Authors:

Serena Silvestro, Giovanni Schepici, Placido Bramanti, and Emanuela Mazzon


Published in Molecules

November 2020

Abstract

The Cannabis sativa plant contains more than 120 cannabinoids. With the exceptions of ∆9-Cannabidiol (CBD) is a non-psychoactive phytocannabinoid known for its beneficial effects including antioxidant and anti-inflammatory properties. Moreover, CBD is a compound with antidepressant, anxiolytic, anticonvulsant and antipsychotic effects. Thanks to all these properties, the interest of the scientific community for it has grown. Indeed, CBD is a great candidate for the management of neurological diseases. The purpose of our review is to summarize the in vitro and in vivo studies published in the last 15 years that describe the biochemical and molecular mechanisms underlying the effects of CBD and its therapeutic application in neurological diseases. CBD exerts its neuroprotective effects through three G protein coupled-receptors (adenosine receptor subtype 2A, serotonin receptor subtype 1A and G protein-coupled receptor 55), one ligand-gated ion channel (transient receptor potential vanilloid channel-1) and one nuclear factor (peroxisome proliferator-activated receptor γ). Moreover, the therapeutical properties of CBD are also due to GABAergic modulation. In conclusion, CBD, through multi-target mechanisms, represents a valid therapeutic tool for the management of epilepsy, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.

Open Access

FULL PAPER >>

DOI: doi.org/10.3390/molecules25215186

Citation:

Silvestro, S., Schepici, G., Bramanti, P., & Mazzon, E. (2020). Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease. Molecules, 25(21), 5186.